Best Peptides for Longevity

The five peptides with the strongest evidence for longevity-related mechanisms available to South African researchers in 2026 are NAD+, GHK-Cu, MOTS-C, Epithalon, and BPC-157.

• NAD+ (pen or IV), mitochondrial co-factor; R900 per 1,000 mg pen at Health & Fitness ZA [3]
• GHK-Cu, copper tripeptide; collagen synthesis and wound repair; R740 per pen [3]
• MOTS-C, mitochondrial-derived peptide; AMPK (adenosine monophosphate-activated protein kinase) activation and insulin sensitivity [1]
• Epithalon, tetrapeptide; telomerase activation in preclinical models [1]
• BPC-157, gut-derived; tissue repair and anti-inflammatory signalling

Human longevity outcome trials remain limited for most of these compounds. NAD+ precursor research is the most clinically advanced, with 2024–2025 randomised trials reporting improved mitochondrial function and insulin sensitivity in older adults [1]. MOTS-C, GHK-Cu, and Epithalon are largely preclinical or early-phase in humans as of Q1 2026 [1]. SAHPRA (South African Health Products Regulatory Authority) classifies therapeutic peptides intended for human administration as medicines under the Medicines and Related Substances Act, meaning unregistered products may only be accessed via Section 21 or clinical-trial frameworks [4].

Why Peptides for Longevity? The Science in 2026

Longevity peptides are short-chain amino acid sequences that modulate specific biological pathways: mitochondrial energy production, collagen synthesis, telomerase activation, and inflammatory signalling. These pathways deteriorate with age. Unlike broad-spectrum supplements, each peptide targets a defined mechanism, which makes them tractable for research even when clinical outcome data remains thin.

The Core Mechanisms

Four pathways dominate the current evidence base.

Mitochondrial function and NAD+ metabolism is the most clinically advanced area. Multiple 2024–2025 randomised trials in older adults and metabolic-syndrome populations reported improved mitochondrial efficiency and insulin sensitivity following NAD+ precursor supplementation [1]. The effect is mechanistically coherent: NAD+ is a rate-limiting co-factor for sirtuins and PARP (poly-ADP-ribose polymerase) enzymes, both of which decline with age and govern DNA repair and cellular stress responses.

AMPK activation is the pathway through which MOTS-C, a mitochondrial-derived peptide, exerts its metabolic effects. Early-phase human work published in 2024–2025 showed improved insulin sensitivity and exercise capacity in middle-aged subjects, though no large longevity-outcome trial has reported results yet [1].

Collagen and tissue remodelling via GHK-Cu operates through fibroblast stimulation and antioxidant gene upregulation. Peer-reviewed human data from 2023–2025 is largely dermatologic, small trials confirming improved collagen deposition and wound repair, rather than systemic longevity endpoints [1]. GHK-Cu's relevance to skin biology is covered in depth on the Best Peptides for Skin page.

Telomerase activation is Epithalon's proposed mechanism. The foundational telomerase research dates to the 2010s; Epithalon's preclinical rodent data shows extended lifespan and improved healthspan markers, but human trials as of Q1 2026 remain early-phase. The theoretical risk of dysregulated telomerase activity in individuals with latent neoplasms warrants caution [1].

The Research-to-Clinic Gap

Epithalon is a tetrapeptide with telomerase-activating effects in preclinical models [1]. That single sentence is about as far as the evidence permits for a human longevity claim in 2026. Animal models and surrogate biomarker trials are not equivalent to randomised human lifespan data, and no peptide on this list has completed a powered, long-term human longevity trial. MOTS-C's metabolic benefits also intersect with muscle preservation and exercise capacity, an angle explored further on the Best Peptides for Muscle Growth page. The science is promising and mechanistically sound; it is not yet conclusive.

Best Longevity Peptides Available in South Africa, 2026 Comparison

Five peptides with documented longevity-relevant mechanisms are currently accessible to South African researchers and clinicians, from in-stock retail options to import-only research vials.

Peptide	Mechanism	Dose Range	ZAR Price (2026)	Local Availability	Research Status
NAD+ Pen	NAD+ repletion; mitochondrial biogenesis; sirtuin activation	10–30 mg per dose; 1,000 mg total	R900–R1,800 [3]	In stock (retail)	Human trials: surrogate biomarkers confirmed; lifespan data pending
GHK-Cu Pen	Fibroblast stimulation; antioxidant gene upregulation; collagen remodelling	50 mg pre-mixed; dose per protocol	R740–R1,400 [3]	In stock (retail)	Human data: dermatologic endpoints; systemic longevity endpoints unconfirmed
MOTS-C	Mitochondrial-derived peptide; AMPK activation; insulin sensitisation	32-dose pen; approximately 5–10 mg per dose	R1,500–R2,100	Import-only (verify at time of order)	Early-phase human: metabolic and exercise-capacity signals; no longevity-outcome trial completed
Epithalon	Telomerase activation; epigenetic regulation	20 mg vial; 5–10 mg per cycle	R800–R1,200	Import-only (verify at time of order)	Preclinical rodent lifespan data; human trials early-phase as of Q1 2026
IV NAD+ (clinic)	As above; higher-dose systemic delivery	Per-infusion protocol	R400 per treatment [1]	In-clinic (e.g., GenX Clinics)	Established clinical use for NAD+ repletion; longevity endpoints not formally trialled

ZAR retail prices sourced from Health & Fitness ZA [3] and GenX Clinics [1]; pen prices for MOTS-C and Epithalon are JCSG supplier estimates for Q1 2026 and must be confirmed at point of purchase. Import-only status reflects the absence of publicly listed South African e-commerce stock for those peptides as of Q1 2026.

Availability Notes

Stock status matters as much as price for South African buyers. NAD+ and GHK-Cu pens are the most accessible, listed without pre-order or sold-out flags on local retail platforms [3]. MOTS-C and Epithalon are not listed in any South African peptide-pen collection identified as of Q1 2026, placing them in the import-only category where exchange-rate exposure and customs clearance add cost and lead time.

SAHPRA classifies most therapeutic peptides intended for human administration as medicines under the Medicines and Related Substances Act, meaning unregistered products may only be accessed via Section 21 authorisation or approved clinical-trial frameworks [6]. Researchers sourcing import-only peptides should confirm regulatory status before ordering.

NAD+ Pen (R900–R1,800): broadest local availability; retail stock confirmed [3]

GHK-Cu Pen (R740–R1,400): retail stock confirmed; also relevant to skin regeneration. See Best Peptides for Skin for dermatologic dosing context [3]

MOTS-C (R1,500–R2,100 est.): import-only; metabolic and muscle-preservation applications overlap with Best Peptides for Muscle Growth

Epithalon (R800–R1,200 est.): import-only; contraindicated in individuals with active or recent malignancy given theoretical telomerase dysregulation risk [7]

IV NAD+ clinic infusion (R400 per treatment): lowest per-session cost; requires clinic attendance. GenX Clinics pricing confirmed for 2024–2025 [1]

NAD+ Peptide Pens: Cellular Energy & Mitochondrial Support

NAD+ declines by roughly 50% between age 40 and 60, and restoring intracellular NAD+ levels is one of the most mechanistically grounded strategies in longevity research today. That decline directly impairs sirtuin activity. Sirtuins are NAD+-dependent deacetylases that regulate DNA repair, mitochondrial biogenesis, and inflammatory signalling, making NAD+ repletion a logical upstream intervention rather than a symptomatic one.

The peptide-pen format makes dosing practical for self-administering researchers. A 1,000 mg NAD+ pen allows titration across 10 mg, 20 mg, and 30 mg increments per injection, which matters because higher doses correlate with more pronounced flushing and transient nausea during IV infusion protocols [6]. Subcutaneous delivery via pen reduces that side-effect burden while preserving bioavailability for most users. Health & Fitness ZA lists the NAD+ Pen 1000 mg at R900 as of late 2025 to early 2026 [1], making it the most price-accessible entry point for local researchers.

For those preferring a clinic-administered route, GenX Clinics prices its NovaNAD+ IV infusion at R400 per treatment [6]. This option offers lower per-session cost but requires attendance and does not offer the dosing flexibility of a pen. The two formats serve different use cases: the pen suits researchers running structured self-administration protocols; the infusion suits individuals who want practitioner oversight or who are new to NAD+ therapy.

The mechanistic case for NAD+ in longevity rests on sirtuin activation (particularly SIRT1 and SIRT3), PARP-1 DNA repair activity, and mitochondrial complex I function. Studies on NAD+ precursors such as NMR (nicotinamide mononucleotide riboside) and NMN (nicotinamide mononucleotide) published between 2022 and 2025 report improved insulin sensitivity and mitochondrial respiration in older adults and metabolic-syndrome populations, though most of this work involves oral precursors rather than injectable NAD+ directly. Injectable NAD+ bypasses first-pass metabolism and is the format most commonly used in South African clinic settings.

NAD+ pens are the most broadly available longevity peptide in South Africa, with confirmed retail stock and no pre-order flags as of Q1 2026 [1]. They are most relevant to researchers aged 40 and above, individuals with documented mitochondrial dysfunction, or biohackers tracking biological age via methylation clocks. If your protocol also includes GHK-Cu for tissue repair, the two peptides are complementary. GHK-Cu's collagen and skin-regeneration applications are covered in detail at Best Peptides for Skin.

GHK-Cu Copper Tripeptide: Collagen & Tissue Regeneration

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide that upregulates collagen I and III synthesis, accelerates wound healing, and suppresses pro-inflammatory cytokines. First isolated in the 1970s, it accumulated a substantial body of dermatological and tissue-repair literature through the 2010s and into the 2020s.

The mechanism centres on GHK-Cu's ability to activate TGF-β (transforming growth factor beta) pathways and stimulate fibroblast proliferation, driving collagen and elastin deposition in ageing or damaged tissue. Peer-reviewed work published between 2023 and 2025 on GHK-Cu in humans is concentrated in dermatologic applications, improved collagen deposition, wound repair, and skin elasticity in adult subjects, rather than systemic longevity endpoints [1]. That distinction matters: the systemic longevity case for GHK-Cu remains largely preclinical, while the skin and connective-tissue data in humans is more developed.

For researchers running structured protocols, JCSG stocks a 50 mg pre-mixed GHK-Cu pen at R1,200 (2026 pricing). The pre-mixed format eliminates the reconstitution step required with lyophilised vials, reducing preparation error and contamination risk for self-administration protocols. Health & Fitness ZA also lists a GHK-Cu pen at R740 [3], though the concentration and formulation should be confirmed directly before comparing on price alone.

On safety, GHK-Cu is generally well-tolerated at cosmetic and research doses, with reported side effects limited to mild local reactions such as pruritus or injection-site irritation. Copper overload is a theoretical concern at high or prolonged doses, though it has not been prominent in published literature at standard research quantities [1].

GHK-Cu sits at the intersection of two research areas covered on this site. Its collagen and skin-regeneration applications are examined in depth at Best Peptides for Skin, while researchers combining it with metabolically active peptides like MOTS-C for broader healthspan protocols may also find Best Peptides for Muscle Growth relevant to their stack design.

MOTS-C: Mitochondrial Function & Metabolic Longevity

MOTS-C is a 16-amino-acid peptide encoded within the mitochondrial genome, making it one of the few known peptides of mitochondrial rather than nuclear origin. First characterised around 2015, it functions as a metabolic regulator, activating AMPK pathways to improve glucose uptake, support mitochondrial biogenesis, and enhance exercise capacity [1].

The mechanism distinguishes MOTS-C from most longevity peptides. Rather than acting on telomere length or growth-factor signalling, it targets the metabolic axis directly: animal studies show improved glucose tolerance, increased mitochondrial density in skeletal muscle, and resistance to diet-induced obesity at studied doses [1]. The connection to longevity is metabolic. Sustained insulin sensitivity and mitochondrial efficiency are among the strongest correlates of healthspan in the published ageing literature.

Human research is early-phase. Pilot and observational work from 2024 to 2025 suggests possible improvements in insulin sensitivity and exercise capacity in middle-aged subjects, but no large, longevity-focused outcome trial has reported results yet [1]. Treat MOTS-C as a promising but still-investigational compound, not an established intervention.

On dosing, the Body Pharm MOTS-C 32-dose pen, stocked by JCSG at R1,800 (2026 pricing), delivers 10 mg per dose. That format suits structured research protocols where consistent dosing and sterility matter. No MOTS-C pen was listed in Health & Fitness ZA's peptide-pen collection as of early 2026 [5], which suggests JCSG is currently the more accessible local source for this compound.

Reported side effects in animal studies include transient hypoglycaemia and altered appetite; human pilot data points to possible gastrointestinal discomfort or fatigue, though long-term carcinogenicity and reproductive safety data remain absent [1]. Anyone with a history of hypoglycaemia or metabolic disorders should factor that into protocol design.

Researchers building a stack around MOTS-C for metabolic longevity may find it pairs logically with GHK-Cu, which addresses connective-tissue and cellular-repair pathways that MOTS-C does not target. The muscle-performance dimension of MOTS-C also overlaps with protocols covered at Best Peptides for Muscle Growth, where exercise capacity and metabolic health intersect with body-composition goals.

Epithalon: Telomerase Activation & Circadian Longevity

Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal gland's natural peptide Epithalamin. Vladimir Khavinson, a Russian researcher, developed it from the 1980s onward and studied it primarily for its ability to activate telomerase, extend telomere length, and regulate circadian and neuroendocrine function in ageing organisms [7].

The mechanism is relatively well-characterised at the preclinical level. Epithalon upregulates telomerase activity in somatic cells, which in theory slows the telomere shortening associated with cellular senescence. Separately, it appears to restore pineal melatonin secretion in aged animals, connecting to circadian rhythm normalisation and downstream immune modulation [7]. These two pathways, telomere maintenance and circadian regulation, make Epithalon conceptually distinct from the metabolic and repair-focused peptides covered earlier in this article.

The evidence base is heavily weighted toward Russian-language animal studies from the 1990s and early 2000s. Rodent models consistently show extended lifespan and reduced tumour incidence, but these studies have not been replicated in large Western peer-reviewed trials [7]. Human data remains sparse: small observational studies suggest improvements in melatonin levels and some immune markers in elderly subjects, but no randomised controlled trial with longevity endpoints has been published in a major indexed journal as of early 2026 [7].

Theoretical risks deserve attention. Dysregulated telomerase activity carries a plausible oncogenic risk, and Epithalon is generally considered contraindicated in individuals with active or recent malignancy [7]. Long-term carcinogenicity and reproductive safety data are absent, a meaningful gap given the telomerase mechanism.

A typical research protocol uses 20 mg total, administered as 5 mg daily for four consecutive days, repeated one to two times per year. Body Pharm Epithalon 20 mg is stocked by JCSG at R950 (2026 pricing). Health & Fitness ZA does not list Epithalon in its peptide-pen collection [3], making JCSG the more accessible local source at this time.

Epithalon is a research-stage compound. Researchers willing to accept the uncertainty of a thin human evidence base and a theoretical oncogenic risk may find it a logical addition to a longevity stack, particularly where circadian disruption or telomere biology is a focus. Its skin-regeneration overlap also connects to the peptide applications covered at Best Peptides for Skin.

How to Choose the Right Longevity Peptide for Your Goals

Your primary longevity priority should drive peptide selection before cost, availability, or stacking complexity enter the picture.

Match the Peptide to the Mechanism

Cellular energy and NAD+ metabolism is the most accessible entry point. NAD+ peptide pens target mitochondrial function and are available locally at R900 per 1,000 mg pen (Health & Fitness ZA, 2026 pricing) [3]. If your focus is metabolic health, insulin sensitivity, or exercise capacity, MOTS-C addresses those endpoints through AMPK activation and mitochondrial reprogramming [5]. For tissue regeneration and systemic repair, GHK-Cu at R740 per pen [3] covers wound healing and collagen synthesis, with the added relevance to skin health covered in the Best Peptides for Skin guide. Telomere biology and circadian regulation point toward Epithalon, though its human evidence base remains the thinnest of the four [7].

Typical Research Doses

Protocols drawn from available literature suggest the following ranges:

• NAD+: 10–30 mg per day
• GHK-Cu: approximately 50 mg per week
• MOTS-C: 10 mg per day
• Epithalon: 10 mg per week, cycled rather than continuous [5][7]

These are research-context figures, not clinical prescriptions.

Stacking Considerations

Two combinations appear most frequently in the current literature. NAD+ paired with MOTS-C targets metabolic longevity from two complementary angles: NAD+ restores substrate availability while MOTS-C drives AMPK-mediated efficiency [5]. GHK-Cu combined with NAD+ addresses systemic regeneration alongside cellular energy, which is relevant if tissue repair or exercise recovery is a secondary goal alongside the metabolic work discussed in Best Peptides for Muscle Growth.

Stacking increases monthly cost substantially. A NAD+ and MOTS-C combination runs R3,000–R5,000 per month at current South African pricing once sourcing, cycling, and any practitioner oversight are factored in. That cost warrants baseline bloodwork, at minimum a metabolic panel and inflammatory markers, so you have something to measure against.

Research vs. Self-Experimentation

None of these compounds carry SAHPRA registration for general human use, meaning clinical access requires a Section 21 framework or practitioner oversight [7]. Self-experimentation with research-grade material sits outside authorised channels and carries regulatory as well as safety risk. A practitioner familiar with peptide protocols, such as those operating through GenX Clinics [1], can provide monitoring and, where applicable, a legal access pathway.

Pricing & Availability: Where to Buy Longevity Peptides in South Africa

JCSG is the primary South African supplier for research-grade longevity peptides, with Q1 2026 pricing as follows:

• NAD+ Pen (1,000 mg): R1,500
• GHK-Cu Pen: R1,200. Also relevant to skin regeneration protocols covered in Best Peptides for Skin
• MOTS-C (32-dose vial): R1,800. Supports metabolic health alongside the exercise-capacity goals discussed in Best Peptides for Muscle Growth
• Epithalon: R950
• Free shipping on orders over R2,000 within South Africa
• Pre-order lead time: 2–4 weeks for MOTS-C and Epithalon when not in stock
• Payment methods: EFT, major credit cards

For comparison, Health & Fitness ZA listed a NAD+ Pen at R900 and a GHK-Cu Pen at R740 in their late-2025 peptide-pen collection [3]. JCSG pricing sits higher, reflecting research-grade sourcing and local quality controls rather than a direct retail model.

Stack Costs vs. Single Peptides

A single-peptide NAD+ protocol runs approximately R1,500 per month at JCSG pricing. A NAD+ and MOTS-C stack reaches R3,300 before any practitioner fees, and a full three-compound stack including GHK-Cu pushes past R4,500 monthly. Bulk or repeat-order discounts apply at JCSG; confirm current terms directly at time of ordering, as these change with stock cycles.

Import Options

MOTS-C and Epithalon are not consistently stocked by South African retail suppliers [3]. When JCSG shows a pre-order status, international research suppliers can fill the gap, though pricing arrives in USD or EUR and converts unfavourably given current exchange rates. Import lead times of 3–6 weeks and potential customs delays make local sourcing preferable where stock permits. Any imported research-grade material used in a human context still falls under SAHPRA's Section 21 framework [4].

Research Status & Safety Considerations

None of the four peptides covered in this guide, NAD+, GHK-Cu, MOTS-C, and Epithalon, are registered with SAHPRA for human therapeutic use. SAHPRA classifies unregistered therapeutic peptides as medicines under the Medicines and Related Substances Act; clinical administration outside a Section 21 authorisation or approved trial framework carries regulatory and legal risk for both practitioner and patient [7]. JCSG supplies these compounds for research purposes only.

Where the Evidence Actually Stands

The human evidence base varies considerably across the four compounds. NAD+ precursor therapies have the strongest clinical record: 2024–2025 randomised trials report improved mitochondrial function, insulin sensitivity, and surrogate ageing biomarkers in older adults and metabolic-syndrome populations, though most involve oral NMN or NR rather than injectable NAD+ pens [2]. GHK-Cu human data through 2023–2025 is concentrated in dermatology, collagen deposition, wound repair, and cosmetic anti-ageing, rather than systemic longevity endpoints; systemic toxicity at cosmetic doses has not been a prominent finding, though copper overload remains a theoretical concern at high or prolonged doses [1]. Its dual relevance to skin biology is covered in more depth in Best Peptides for Skin.

MOTS-C animal studies from 2023–2025 show favourable safety profiles, with occasional transient hypoglycaemia and appetite changes noted at studied doses; early-phase human pilot work suggests possible gastrointestinal discomfort or fatigue, and long-term carcinogenicity and reproductive safety data are absent [2]. Its metabolic and exercise-capacity effects are also relevant to the protocols discussed in Best Peptides for Muscle Growth.

Epithalon is the least validated in Western peer-reviewed literature. Rodent studies show extended lifespan and minimal acute toxicity, but the mechanism, telomerase activation, raises a theoretical concern: dysregulated telomerase activity could promote latent neoplasms or impair immune surveillance [2]. Most expert protocols list active or recent malignancy as a contraindication. No South African practitioners or researchers appear as named authors in 2024–2026 peer-reviewed peptide longevity publications [4].

Practical Safety Notes

• NAD+ infusions: transient flushing, nausea, headache, and chest tightness are reported at higher IV doses; slower infusion rates typically reduce these effects [1]
• GHK-Cu injectable: mild injection-site reactions, pruritus, and local irritation are the most common findings in clinic experience [1]
• MOTS-C: possible transient hypoglycaemia; monitor blood glucose if combining with other metabolic interventions [2]
• Epithalon: contraindicated in individuals with active or recent malignancy; long-term immune effects are unknown [2]

Medical consultation before use is not optional. It is the minimum responsible step given the absence of SAHPRA registration and the gaps in long-term human safety data.

Longevity Peptides vs. Other Anti-Ageing Approaches

Peptides occupy a specific niche in the longevity toolkit: they are research-stage interventions that may amplify the effects of foundational habits, not replace them. Lifestyle, consistent resistance training, adequate sleep, and a calorie-appropriate whole-food diet, remains the only intervention with decades of human outcome data behind it.

Where Peptides Sit in the Stack

The most practical comparison is NAD+ peptide pens versus oral NMN or NR supplements. A NAD+ pen from a South African supplier runs roughly R900–R1,500 per month (Health & Fitness ZA, Q1 2026) [5], while NMN capsules from local health retailers typically cost R400–R800 per month. The pen delivers a defined subcutaneous dose that bypasses first-pass metabolism; the supplement offers oral convenience and a longer safety record in humans. For most people starting out, the supplement is the lower-risk, lower-cost entry point.

MOTS-C is a mitochondria-derived peptide that activates AMPK and improves insulin sensitivity [1]. That mechanism overlaps directly with the metabolic adaptations driven by aerobic and resistance exercise, which means the two are genuinely complementary rather than redundant. Early-phase human work from 2024–2025 suggests improved insulin sensitivity and exercise capacity in middle-aged subjects, though no large outcome trial has confirmed this yet [1]. The same logic applies to best peptides for muscle growth: MOTS-C's metabolic effects are most relevant when exercise stimulus is already present.

GHK-Cu pairs logically with a collagen-supporting diet, adequate protein, vitamin C, and zinc, because the peptide's mechanism involves upregulating collagen synthesis and tissue repair pathways [2]. It does not substitute for dietary substrate; it may accelerate the signalling that uses it. Its dual role in systemic tissue regeneration and skin repair is covered in more depth in best peptides for skin.

Cost-Benefit Reality

Pharmaceuticals such as metformin and rapamycin have larger human evidence bases than any peptide on this list, and metformin in particular is inexpensive and widely available through South African pharmacies under prescription. Peptides cost more, carry more regulatory uncertainty, and have shorter human safety records. The honest framing is that peptides are adjuncts for researchers and biohackers who have already optimised the basics, not a shortcut past them.

Frequently Asked Questions About Longevity Peptides